重组人垂体腺苷酸环化酶激活多肽及其衍生多肽的研制、生物功能筛选及鉴定
|
摘要
垂体腺苷酸环化酶激活肽(pituitary adenylate cyclase activating polypeptide，PACAP)是具有重要生物学功能和极具应用价值的神经多肽。为利用基因工程技术获得非融合的重组人垂体腺苷酸环化酶激活肽(recombinant human PACAP，rhPACAP)，采用rhPACAP与纤维素结合域(cellulose binding domain，CBD)融合表达，并在两者之间引入Xa因子的识别位点(Ile-Glu-Gly-Arg↓)。融合蛋白CBD-PACAP经纤维素亲和层析纯化后，Xa因子酶切释放非融合重组PACAP。HPLC进一步纯化的重组PACAP多肽经Western blot与激光飞行质谱鉴定。制备的rhPACAP具有促进胰腺癌细胞株SW1990胞内cAMP合成的活性，表明其具有生物学活性。
在两个融合蛋白(CBD-PACAP和CBD-IGF)中Xa因子识别位点(Ile-Glu-Gly-Arg↓)前引入7个氨基酸组成的富含甘氨酸柔性短肽(Gly-Thr-Gly-Gly-Gly-Ser-Gly)，经比较Xa因子对引入短肽前、后融合蛋白的酶切效率后发现，短肽的引入不同程度地提高了融合蛋白CBD-IGF和CBD-PACAP对Xa因子的敏感性，此研究结果提供了一种提高Xa因子酶切效率的策略。
为利用蛋白内含肽介导的一步纯化实现重组PACAP(RMPACAP)的高效制备，将目的多肽融合表达在具可诱导剪切功能的亲和纯化标签的N端，实现融合蛋白RMPACAP-intein-CBD的高效表达；融合蛋白经几丁质柱纯化后，硫醇诱导蛋白内含肽自动切割释放目的多肽RMPACAP；所制备的RMPACAP与天然PACAP38相比，在其N端多了一个甲硫氨酸(Met)，但其促进SW1990细胞胞内cAMP生成的活性与PACAP38标准品相同。利用此工艺，1L的菌体培养物可获得22mg的纯度可高达98％的RMPACAP多肽。此研究建立了一种高效制备重组PACAP的方法。
模仿已有的VPAC2受体特异激动剂序列，结合已建立的蛋白内含肽介导的多肽制备工艺，设计并实现4条重组多肽(RMROM、RROM、RMBAY和RBAY)的制备；四条重组多肽(50ng／kg)与高浓度葡萄糖(1.8mmol／kg)共同腹腔注射NIH小鼠时，均有效协助降低血糖；其中RMBAY的降糖作用较其它重组多肽显著，并可有效促进葡萄糖依赖的胰岛素分泌。RMBAY的筛选及其制备方法的建立为开展重组多肽RMBAY治疗Ⅱ型糖尿病的研究奠定基础。
为从分子和细胞水平研究所制备的重组多肽RMPACAP及RMBAY对PACAP的三个受体的选择性(Selectivity)和激动性(Potency)，从分子水平诠释重组多肽的作用机制，构建分别高效表达PACAP三个受体：PAC1、VAPC1和VPAC2的中国仓鼠卵巢(Chinese hamster ovary，CHO)细胞株。RT-PCR鉴定受体基因在mRNA水平的表达；Western blot和荧光免疫法鉴定VPAC1和VPAC2受体的表达。~(125)I-PACAP38配体与受体结合实验检测PAC1受体的表达。重组多肽与~(125)I-PACAP38对受体的竞争结合实验结果显示RMPACAP对三个受体均具有选择性；而RMBAY对VPAC2受体的IC_(50)为70±5nmol／L，对VAPC1受体和PAC1受体的IC_(50)均大于10μmol／L。重组多肽RMBAY促进VPAC2-CHO细胞株胞内cAMP产生的EC_(50)为1.8±0.2nM，RMPACAP的EC_(50)为5.3±0.3nM。RMBAY对VPAC2受体具有特异的选择性和激动性，是VPAC2受体的特异激动剂。RMBAY的筛选和鉴定为具有自主知识产权的VPAC2受体特异激动剂的研究和开发铺垫道路。
为提高多肽的活性和稳定性，尝试利用蛋白内含肽可诱导剪切功能和多肽硫酯环合技术实现RCBAY环肽的制备。激光飞行质谱检测制备产物中含有成分的分子量为4128.10，与环肽的理论值相符。活性检测表明含有重组环肽RCBAY的制备产物与直链肽RMBAY相比，降血糖的作用更显著和持久。本研究提示RCBAY可能成为治疗Ⅱ型糖尿病的更有效的药物。
在实验室水平确定工程菌RMBAY-ER2566的生长曲线，碳源，IPTG诱导时OD_(600)，IPTG用量和诱导时间等参数。初步的探索结果表明：培养菌体至OD_(600)达到0.5-1.0时加入IPTG至工作浓度0.4mmol／L，30℃诱导表达3-4h，或37℃诱导表达2-3h，均能有保证目的蛋白的高效表达。葡萄糖作为碳源抑制目的蛋白的表达。以实验室研究为参考，利用5L发酵罐发酵，3.5L发酵液收获湿重为113g的菌体，其中目的蛋白表达量达到30-35％，可溶性成分占可溶性蛋白的28-30％。工程菌RMBAY-ER2566的发酵为开展RMBAY作为VPAC2型受体特异激动剂的生物学研究及其医学应用奠定基础。
总体上，本文主要利用基因工程原理和技术，结合蛋白内含肽可诱导剪切功能实现重组PACAP及其衍生多肽的高效制备；筛选并鉴定一条可高效协助机体降低血糖的新型VPAC2受体特异激动剂——RMBAY；尝试通过环化提高其活性和稳定性；开展工程菌中试发酵的研究；为具有自主知识产权的VPAC2受体特异激动剂的研究和开发奠定基础。
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptidewith multiple important bioactivities and worthy of medical application. In order toproduce non-fusion recombinant human pituitary adenylate cyclase activatingpolypeptide (rhPACAP) using gene engineering technology, a fusion protein with arecognized site of factor Xa (Ile-Glu-Gly-Arg↓) between CBD (cellulose bindingdomain) and rhPACAP was expressed and purified by cellulose affinitychromatography. Non-fusion rhPACAP was released by the cleavage of factor Xa,then purified by HPLC and identified by Western blot and Laser flying massspectrometry. The preliminary bioactivity assay indicated that the product had theactivity of promoting cAmp in the cell line SW1990 of human pancreas carcinoma.
A short flexible peptide abundant in Gly(Gly-Thr-Gly-Gly-Gly-Ser-Gly) wasadded before the recognized site by factor Xa. The compare of the cleavage efficiencyof factor Xa on both two-group fusion proteins (CBD-IGF and CBD-PACAP) withand without short flexible peptide indicated that the short peptide helped to improvethe sensitivity of fusion protein to factor Xa in different degree. A strategy ofpromoting the cleavage efficiency of factor Xa was presented.
In order to obtain the recombinant human PACAP efficiently by intein-mediatedsingle column purification, the target protein was over-expressed as a fusion to theN-terminus of a self-cleavable affinity tag. After the PACAP-intein-CBD fusionprotein was purified by chitin-affinity chromatography, the self-cleavage activity ofthe intein was induced by thiol and the RMPACAP was released from thechitin-bound intein tag. The activity assay showed that RMPACP, which has an extraMet at its N-terminus compared with the native human PACAP, had the similaractivity of stimulating cAmp accumulation with the standard PACAP38 in theSW1990 cells. Twenty-two milligrams of RMPACAP with the purity over 98% was obtained by single column purification from 1 liter of induced culture. A new efficientproduction procedure of the active recombinant human PACAP was established.
Four recombinant PACAP derived peptides (RMROM, RROM, RMBAY andRBAY) as potential therapies for TypeⅡDiabetes were designed based on theknown agonist of VPAC2 receptor, and were prepared using intein-mediatedpurification system. All peptides (50ng/kg) decreased the level of plasma glucose afterinfused with high concentration glucose (1.8mmol/kg) to the enterocoelia of NIHmouse. RMBAY with the highest activity of reducing the level of plasma glucosestimulated the glucose-dependent insulin secretion. The screening and preparation ofRMBAY laid the foundation for development of RMBAY as potential therapy forType 2 Diabetes.
The receptor-transfected Chinese hamster ovary (CHO) cell clones expressingthree receptors subclasses of PACAP respectively were constructed and selected. Theresults of RT-PCR, immunoflourescence assay and the binding assay of~(125)I-PACAP38 to the receptor showed that three receptors were expressed on threecells (VPAC1-CHO, VPAC2-CHO and PAC1-CHO) respectively. The competitionbinding of ~(125)I-PACAP38 on membranes from CHO cells expressing each of threesubtypes of human PACAP receptors was used to identify the selectivity of RMBAYand RMPACAP on three receptors. RMPACAP competitively displaced~(125)I-PACAP38 on all three receptor subclasses. RMBAY competitively displaced~(125)I-PACAP38 on VPAC2 with a half-maximal inhibitory concentration (IC50) of 70±5nmol/L, whereas the IC50 of RMBAY at human VPAC1 or PAC1 was observedup to 10μmol/L1. RMBAY stimulated the cAmp in VPAC2-CHO cells with ahalf-maximal stimulatory concentration (EC50) of 1.8±0.2nmol/L. Thus, RMBAYis a selective agonist ligand for VPAC2 receptor subclass.
The intein-mediated purification and cyclization of unprotected peptidethioesters were tried to produce a recombinant cyclic peptide (RCBAY) for thepurpose of improving the stability and activity of the peptide. The mass spectrometryassay showed that the products contained the component with the molecular weight of4128.10 consistent with the theoretic value of RCBAY. The mixture containing RCBAY displayed a stronger effect on reducing the level of plasma glucose and lastedlonger time than RMBAY. It was suggested that RCBAY might be a more effectivetherapy for typeⅡdiabetes.
Some parameters were studied, e.g. the growth curve of the engineered strainRMBAY-ER2566, the value of OD_(600) at which the expression of the target protein wasinduced, the amount of IPTG and the time spent on inducing protein expression. Thetarget protein was effectively induced by 0.4mmol/L IPTG for 3-4hr at 30℃or for2-3hr at 37℃, when the OD_(600) of the culture reached 0.5-1. Glucose inhibited theexpression of the target fusion protein. Based on the conditions mentioned above, thestrain was fermented with high density in 5L fermentor. One hundred and thirteengrams of wet bacteria was obtained from 3.5L culture. The expression of target fusionprotein reached 32-35% of total bacterial protein and 28% of the total soluble proteins.The fermentation of the engineered strain RMBAY-ER2566 ensured the furtherresearch and medical development of RMBAY.
All in a word, the study focused on the efficient preparation of recombinantPACAP and its derived peptides, the screening and identification of RMBAY as anovel agonist of VPAC2 receptor with bioactivity of reducing plasma glucose,producing cyclopeptide RCBAY based on RMBAY for improving the bioactivity andstability of the peptide, and the fermentation of the engineered strain for the furtherresearch and application of the novel agonist of VPAC2 receptor of which we ownedthe property right.
在两个融合蛋白(CBD-PACAP和CBD-IGF)中Xa因子识别位点(Ile-Glu-Gly-Arg↓)前引入7个氨基酸组成的富含甘氨酸柔性短肽(Gly-Thr-Gly-Gly-Gly-Ser-Gly)，经比较Xa因子对引入短肽前、后融合蛋白的酶切效率后发现，短肽的引入不同程度地提高了融合蛋白CBD-IGF和CBD-PACAP对Xa因子的敏感性，此研究结果提供了一种提高Xa因子酶切效率的策略。
为利用蛋白内含肽介导的一步纯化实现重组PACAP(RMPACAP)的高效制备，将目的多肽融合表达在具可诱导剪切功能的亲和纯化标签的N端，实现融合蛋白RMPACAP-intein-CBD的高效表达；融合蛋白经几丁质柱纯化后，硫醇诱导蛋白内含肽自动切割释放目的多肽RMPACAP；所制备的RMPACAP与天然PACAP38相比，在其N端多了一个甲硫氨酸(Met)，但其促进SW1990细胞胞内cAMP生成的活性与PACAP38标准品相同。利用此工艺，1L的菌体培养物可获得22mg的纯度可高达98％的RMPACAP多肽。此研究建立了一种高效制备重组PACAP的方法。
模仿已有的VPAC2受体特异激动剂序列，结合已建立的蛋白内含肽介导的多肽制备工艺，设计并实现4条重组多肽(RMROM、RROM、RMBAY和RBAY)的制备；四条重组多肽(50ng／kg)与高浓度葡萄糖(1.8mmol／kg)共同腹腔注射NIH小鼠时，均有效协助降低血糖；其中RMBAY的降糖作用较其它重组多肽显著，并可有效促进葡萄糖依赖的胰岛素分泌。RMBAY的筛选及其制备方法的建立为开展重组多肽RMBAY治疗Ⅱ型糖尿病的研究奠定基础。
为从分子和细胞水平研究所制备的重组多肽RMPACAP及RMBAY对PACAP的三个受体的选择性(Selectivity)和激动性(Potency)，从分子水平诠释重组多肽的作用机制，构建分别高效表达PACAP三个受体：PAC1、VAPC1和VPAC2的中国仓鼠卵巢(Chinese hamster ovary，CHO)细胞株。RT-PCR鉴定受体基因在mRNA水平的表达；Western blot和荧光免疫法鉴定VPAC1和VPAC2受体的表达。~(125)I-PACAP38配体与受体结合实验检测PAC1受体的表达。重组多肽与~(125)I-PACAP38对受体的竞争结合实验结果显示RMPACAP对三个受体均具有选择性；而RMBAY对VPAC2受体的IC_(50)为70±5nmol／L，对VAPC1受体和PAC1受体的IC_(50)均大于10μmol／L。重组多肽RMBAY促进VPAC2-CHO细胞株胞内cAMP产生的EC_(50)为1.8±0.2nM，RMPACAP的EC_(50)为5.3±0.3nM。RMBAY对VPAC2受体具有特异的选择性和激动性，是VPAC2受体的特异激动剂。RMBAY的筛选和鉴定为具有自主知识产权的VPAC2受体特异激动剂的研究和开发铺垫道路。
为提高多肽的活性和稳定性，尝试利用蛋白内含肽可诱导剪切功能和多肽硫酯环合技术实现RCBAY环肽的制备。激光飞行质谱检测制备产物中含有成分的分子量为4128.10，与环肽的理论值相符。活性检测表明含有重组环肽RCBAY的制备产物与直链肽RMBAY相比，降血糖的作用更显著和持久。本研究提示RCBAY可能成为治疗Ⅱ型糖尿病的更有效的药物。
在实验室水平确定工程菌RMBAY-ER2566的生长曲线，碳源，IPTG诱导时OD_(600)，IPTG用量和诱导时间等参数。初步的探索结果表明：培养菌体至OD_(600)达到0.5-1.0时加入IPTG至工作浓度0.4mmol／L，30℃诱导表达3-4h，或37℃诱导表达2-3h，均能有保证目的蛋白的高效表达。葡萄糖作为碳源抑制目的蛋白的表达。以实验室研究为参考，利用5L发酵罐发酵，3.5L发酵液收获湿重为113g的菌体，其中目的蛋白表达量达到30-35％，可溶性成分占可溶性蛋白的28-30％。工程菌RMBAY-ER2566的发酵为开展RMBAY作为VPAC2型受体特异激动剂的生物学研究及其医学应用奠定基础。
总体上，本文主要利用基因工程原理和技术，结合蛋白内含肽可诱导剪切功能实现重组PACAP及其衍生多肽的高效制备；筛选并鉴定一条可高效协助机体降低血糖的新型VPAC2受体特异激动剂——RMBAY；尝试通过环化提高其活性和稳定性；开展工程菌中试发酵的研究；为具有自主知识产权的VPAC2受体特异激动剂的研究和开发奠定基础。
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptidewith multiple important bioactivities and worthy of medical application. In order toproduce non-fusion recombinant human pituitary adenylate cyclase activatingpolypeptide (rhPACAP) using gene engineering technology, a fusion protein with arecognized site of factor Xa (Ile-Glu-Gly-Arg↓) between CBD (cellulose bindingdomain) and rhPACAP was expressed and purified by cellulose affinitychromatography. Non-fusion rhPACAP was released by the cleavage of factor Xa,then purified by HPLC and identified by Western blot and Laser flying massspectrometry. The preliminary bioactivity assay indicated that the product had theactivity of promoting cAmp in the cell line SW1990 of human pancreas carcinoma.
A short flexible peptide abundant in Gly(Gly-Thr-Gly-Gly-Gly-Ser-Gly) wasadded before the recognized site by factor Xa. The compare of the cleavage efficiencyof factor Xa on both two-group fusion proteins (CBD-IGF and CBD-PACAP) withand without short flexible peptide indicated that the short peptide helped to improvethe sensitivity of fusion protein to factor Xa in different degree. A strategy ofpromoting the cleavage efficiency of factor Xa was presented.
In order to obtain the recombinant human PACAP efficiently by intein-mediatedsingle column purification, the target protein was over-expressed as a fusion to theN-terminus of a self-cleavable affinity tag. After the PACAP-intein-CBD fusionprotein was purified by chitin-affinity chromatography, the self-cleavage activity ofthe intein was induced by thiol and the RMPACAP was released from thechitin-bound intein tag. The activity assay showed that RMPACP, which has an extraMet at its N-terminus compared with the native human PACAP, had the similaractivity of stimulating cAmp accumulation with the standard PACAP38 in theSW1990 cells. Twenty-two milligrams of RMPACAP with the purity over 98% was obtained by single column purification from 1 liter of induced culture. A new efficientproduction procedure of the active recombinant human PACAP was established.
Four recombinant PACAP derived peptides (RMROM, RROM, RMBAY andRBAY) as potential therapies for TypeⅡDiabetes were designed based on theknown agonist of VPAC2 receptor, and were prepared using intein-mediatedpurification system. All peptides (50ng/kg) decreased the level of plasma glucose afterinfused with high concentration glucose (1.8mmol/kg) to the enterocoelia of NIHmouse. RMBAY with the highest activity of reducing the level of plasma glucosestimulated the glucose-dependent insulin secretion. The screening and preparation ofRMBAY laid the foundation for development of RMBAY as potential therapy forType 2 Diabetes.
The receptor-transfected Chinese hamster ovary (CHO) cell clones expressingthree receptors subclasses of PACAP respectively were constructed and selected. Theresults of RT-PCR, immunoflourescence assay and the binding assay of~(125)I-PACAP38 to the receptor showed that three receptors were expressed on threecells (VPAC1-CHO, VPAC2-CHO and PAC1-CHO) respectively. The competitionbinding of ~(125)I-PACAP38 on membranes from CHO cells expressing each of threesubtypes of human PACAP receptors was used to identify the selectivity of RMBAYand RMPACAP on three receptors. RMPACAP competitively displaced~(125)I-PACAP38 on all three receptor subclasses. RMBAY competitively displaced~(125)I-PACAP38 on VPAC2 with a half-maximal inhibitory concentration (IC50) of 70±5nmol/L, whereas the IC50 of RMBAY at human VPAC1 or PAC1 was observedup to 10μmol/L1. RMBAY stimulated the cAmp in VPAC2-CHO cells with ahalf-maximal stimulatory concentration (EC50) of 1.8±0.2nmol/L. Thus, RMBAYis a selective agonist ligand for VPAC2 receptor subclass.
The intein-mediated purification and cyclization of unprotected peptidethioesters were tried to produce a recombinant cyclic peptide (RCBAY) for thepurpose of improving the stability and activity of the peptide. The mass spectrometryassay showed that the products contained the component with the molecular weight of4128.10 consistent with the theoretic value of RCBAY. The mixture containing RCBAY displayed a stronger effect on reducing the level of plasma glucose and lastedlonger time than RMBAY. It was suggested that RCBAY might be a more effectivetherapy for typeⅡdiabetes.
Some parameters were studied, e.g. the growth curve of the engineered strainRMBAY-ER2566, the value of OD_(600) at which the expression of the target protein wasinduced, the amount of IPTG and the time spent on inducing protein expression. Thetarget protein was effectively induced by 0.4mmol/L IPTG for 3-4hr at 30℃or for2-3hr at 37℃, when the OD_(600) of the culture reached 0.5-1. Glucose inhibited theexpression of the target fusion protein. Based on the conditions mentioned above, thestrain was fermented with high density in 5L fermentor. One hundred and thirteengrams of wet bacteria was obtained from 3.5L culture. The expression of target fusionprotein reached 32-35% of total bacterial protein and 28% of the total soluble proteins.The fermentation of the engineered strain RMBAY-ER2566 ensured the furtherresearch and medical development of RMBAY.
All in a word, the study focused on the efficient preparation of recombinantPACAP and its derived peptides, the screening and identification of RMBAY as anovel agonist of VPAC2 receptor with bioactivity of reducing plasma glucose,producing cyclopeptide RCBAY based on RMBAY for improving the bioactivity andstability of the peptide, and the fermentation of the engineered strain for the furtherresearch and application of the novel agonist of VPAC2 receptor of which we ownedthe property right.
引文
1 Miyata A, Arimura A, Dahl R R, Minamino N, Uehara A, Jiang L, Culler M D and Coy D H. Isolation of a novel 38residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun Commun, 1989,164(1): 567-574
2 Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept. 1992, 37(3): 287-303.
3 Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuro-endocrine and endocrine interaction. Front Neuroendocrinol.1995, 16(1): 53-88.
4 Ohkubo S, Kimura C, Ogi K, Okazaki K, Hosoya M, Onda H, Miyata A, Arimura A, Fujino M. Primary structure and characterization of the precursor to human pituitary adenylate cyclase activating polypeptide. DNA Cell Biol. 1992,11(1): 21-30.
5 Chattel N , Tonon M C , Vaudry H. Primary structure of frog pituitary adenylate cyclase activing polypeptide ( PACAP) and effects of ovine PACAP on frog pituitary.Endocrinology. 1991, 129 (6): 3367-3371
6 Shioda S, Shuto Y, Somogyvari-Vigh A, Legradi G, Onda H, Coy D H, Nakajo S and Arimura A. Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain. Neurosci Res. 1997, 28(4):345-354
7 Wei Y, Mojsov S. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J Neuroendocrinol.1996,8(11): 811-817
8 Qiao L P, Li X L. Resent development of research on pituitary adenylate cyclase activating polypeptide and its receptors. J Modern Clinical Medical Bioengineering.2003, 9(1):61-63
9 David Vaudry, Bruno J. Gonzalez, Magali Basille, Laurent Yon, Alain Fournier and Hubert Vaudry. Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors:From Structure to Function. Pharmacological Reviews, 2000, 52(2): 269-324
10 Harmar A J, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna J R.Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). Pharmacol Rev, 1998, 50(2): 265-270.
11 Kamaishi H, Endoh T, Suzuki TMultiple signal pathways coupling VIP and PACAP receptors to calcium channels in hamster submandibular ganglion neurons. Auton Neurosci. 2004 Mar 31;111(1):15-26.
12 See V, Koch B, Loeffier JP. C2-ceramide and reactive oxygen species inhibit pituitary adenylate cyclase activating polypeptide (PACAP) - induced cyclic -AMP- dependent signalling pathway. J Neurochem, 2001,76(3) :778-788
13 Van Rampelbergh J, Poloczek P, Francoys I, Delporte C, Winand J, Robberecht P, Waelbroeck MThe pituitary adenylate cyclase activating polypeptide (PACAP Ⅰ) and VIP (PACAP Ⅱ VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochim Biophys Acta. 1997 Jun 27;1357(2):249-255.
14 Mazzocchi G, Malendowicz LK, Neri G, Andreis PG, Ziolkowska A, Gottardo L, Nowak KW, Nussdorfer GG. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland, Int J Mol Med. 2002 Mar;9(3):233-43.
15 Sacchetti B, Lorenzini CA, Baldi E, Bucherelli C, Roberto M, Tassoni G, Brunelli M Pituitary adenylate cyclase-activating polypeptide hormone (PACAP) at very low dosages improves memory in the rat. Neurobiol Learn Mere. 2001 Jul;76(1):1-6.
16 Hashimoto H, Shintani N, Tanaka K, Mori W, Hirose M, Matsuda T, Sakaue M, Miyazaki J, Niwa H, Tashiro F, Yamamoto K, Koga K, Tomimoto S, Kunugi A, Suetake S, Baba A Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP) Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13355-60. Epub 2001 Oct 30.
17 Yuhara A, Nishio C, Abiru Y, Hatanaka H, Takei N. PACAP has a neurotrophic effect on cultured basal forebrain cholinergic neurons from adult rats. Brain Res Dev Brain Res. 2001 Nov 26;131(1-2):41-5.
18 Somogyvari-Vigh A, Pan W, Reglodi D, Kastin AJ, Arimura A. Effect of middle cerebral artery occlusion on the passage of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier in the rat. Regul Pept. 2000 Jul 28;91(1-3):89-95.
19 董艳，何成，韩唏，垂体腺苷酸环化酶激活肽减轻大鼠缺血性 脑水肿作用的实验研究，中国应用生理学杂志，2002，18(2)：121-31
20 Zhou CJ, Shioda S, Yada T, Inagaki N, Pleasure SJ, Kikuyama S. PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr Protein Pept Sci. 2002 Aug;3(4):423-39.
21 Journot L, Spengler D, Pantaloni C, Dumuis A, Sebben M and Bockaert J. The PACAP receptor: Generation by alternative splicing of functional diversity among G protein-coupled receptors in nerve cells. Semin Cell Biol,l994, 5(4): 263-272
22 Cazillis M, Gonzalez BJ, Billardon C, Lombet A, Fraichard A, Samarut J, Gressens P, Vaudry H, Rostene W. VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells. Eur J Neurosci. 2004 Feb;19(4):798-808.
23 Chang Q, Deng Y P, Liu S H, Morphologic study on PACAP protecting vascular smooth muscle cell from damage by LDL. Progress of Anatomical Sciences 1999; 5:347-349.
24 Linden A, Hansson, L Andersson A, Palmqvist M, Arvidsson P, Lofdahl C-G, Larsson P, Lotvall J. Bronchodilation by an inhaled VPAC2 receptor agonist in patients with stable asthma. Thorax 2003;58:217-221 (http://thorax.bmjjournals.com/cgi/content/full/58/3/217)
25 Akesson L, Ahren B, Manganiello VC, Hoist LS, Edgren G, Degerman E. Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes. Endocrinology. 2003 Dec;144(12):5293-9. Epub 2003 Aug 28.
26 West AP, McKinnell C, Sharpe RM, Saunders PT. Pituitary adenylate cyclase activating polypeptide can regulate testicular germ cell protein synthesis in vitro. J Endocrinol. 1995 Feb;144(2):215-23.
27 Guidone G, Muller D, Vogt K, Mukhopadhyay AK. Characterization of VIP and PACAP receptors in cultured rat penis corpus cavernosum smooth muscle cells and their interaction with guanylate cyclase-B receptors. Regul Pept. 2002 Oct 15;108(2-3):63-72..
28 Ko C, In Y H, Park-Sarge O K. Role of progesterone receptor activation in pituitary adenylate cyclase activating polypeptide gene expression in rato vary.Endocrinology, 1999, 140 (11):5185—5194
29 Delgado M, Abad C, Martinez C, Juarranz MG, Leceta J, Ganea D, Gomariz RP.PACAP in immunity and inflammation. Ann N Y Acad Sci. 2003 May;992:141-57.
30 Abad C, Martinez C, Leceta J, Gomariz RP, Delgado M. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol. 2001 Sep 15;167(6):3182-9.
31 Martinez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodriguez-Henche N, Brabet P, Leceta J, Gomariz RP. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci USA. 2002 Jan 22;99(2): 1053-8. Epub 2002 Jan 15.
32 Pozo D. VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Meal 2003 May;9(5):211-7.
33 Hannibal J, Hindersson P, Knudsen SM, Georg B, Fahrenkrug J. The photopigment melanopsin is exclusively present in pituitary adenylate cyclase-activating polypeptide-containing retinal ganglion cells of the retinohypothalamic tract. J Neurosci. 2002 Jan 1;22(1):RC191.
34 杜鹃，王刚，孔德虎，垂体腺苷酸环化酶激活肽与2型糖尿病，国外医学内分泌学分册，2003，23：7-9
35 Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands. Mol Pharmacol. 1999 Dec;56(6): 1280-7.
36. Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor. Peptides. 2000 Oct;21(10): 1543-9.
37 Igarashi H, Ito T, Pradhan Y K, Mantey S A, Hou W, Coy D H, Jensen R T. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC2 receptors in human and rat and comparison to the pharmacophore for VPAC1 receptors, JPET, 2002 303(2):445-460
38 Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J, Dela Cruz F, Peng X, Chen H, Yung SL, Hamren S, Livingston JN, Pan CQ. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes. 2002 May;51(5):1453-60.
39 Umemoto N, Ohya Y, Anraku Y. VMA11, a novel gene that encodes a putative proteolipid, is indispensable for expression of yeast vacuolar membrane H(+)-ATPase activity. J Biol Chem. 1991 Dec 25;266(36):24526-32..
40 Paulus H. Protein splicing: A novel form of gene expression and paradigm for self2catalyzed protein rearrangements. Pure and Aplied Chemistry, 1998,70(1): 1-8.
41 Lambowitz AM, Belfort M. Introns as mobile genetic elements. Annu Rev Biochem. 1993;62:587-622.
42 Xu M Q, Evans T C Jr. Intein-mediated ligation and cyclization of expressed proteins. Methods, 2001, 24(3): 257-27
43 Xu M Q, Paulus H, Chong S. Fusions to self-splicing inteins for protein purification. Methods Enzymol, 2000,326: 376-41
44 Evans T CJr, Benner J, Xu MQ. The cyclization and polymerization of bacterially expressed proteins using modified self2splicing inteins. JBiol Chem, 1999, 274(26): 18359-18363
45 Scott C P, Abel2Santos E, Wall M, Wahnon D C, Benkovic S J Production of cyclic peptides and proteins in vivo. Proc Natl Acad Sci USA,1999,96 (24): 13638-1364
46 Otomo T, Teruya K, Uegaki K, Yamazaki T, Kyogoku Y. Improved segmental isotope labeling of proteins and application to a larger pro2 tein. J Biomol NMR, 1999, 14(2): 105-114
47 许乃武，基因工程原理，第二册，第三章，第8节．
48 Wei Y, Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiologica Scandinavica, 1996, 157(3): 355-362
49 Schafer H, Lettau P, Trauzold A, Banasch M, Schmidt WE. Human PACAP response gene 1 (p22/PRG1): proliferation associated expression in pancreatic carcinoma cells. Pancreas, 1999, 8(4):378-84
50 Elli nger S, Mach M, Korn K, Jahn G. Cleavage and purification of prokaryotically expressed HIV gag and env fusion proteins for detection of HIV antibodies in the ELISA. Virology,1991,180(2): 811-813.
51 Guan K L, Dixon J E, Eukaryotic proteins expressed in E. coli an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-trans-ferase. Anal Biochem, 1991,192(2) :262-268
52 Zheng Rong, Hu Yi, Zhu Chunbao, et al. Cloning of IL-2 gene in plasmid pMAL-cR1 and expression and purification of IL-2 protein, Chinese Journal of Parmaceuticals, 1994,25(6):243-246
53 Feng Dan, Yuan Yong, Zhang Yingmei, et al. Citraconic anhydride modification on the recombinant protein expressed in E. coli. Prog Biochem Biophys, 1996,23(6):541-544
54 Newton D L, Xue Y, Olson K A, et al. Angiogenin single-chain immunofusions:influence of peptide linkers and spacers between fusion proteins domains.Biochemistry, 1996,35(2):545-553
55 Liu X B, Li S H, Liang X B, Kong X Y. A system of efficient expression and rapid purification of recombinant polypeptides. Bull Acad Mi Med Sci, 1996,120(1):62-65
56 He M, Jin L, Austen B. Specificity of factor Xa in the cleavage of fusion proteins.J Protein Chem, 1993 ,12(1):1-5
57 Zhao M, Wang G, Du B, Nie S X, Jiang R L. Stimulation effect of PACAP on the growth of cell line JF3O5 of human pancreas carcinoma. J Chin Med Univ,2001,30(3):204-208
58 Muller A, Lutz-Bucher B, Kienlen-Campard P, Koch B, Loeffler J P. Continuous activation of pituitary adenylate cyclase-activating polypeptide receptors elicits antipodal effects on cyclic AMP and inositol phospholipid signaling pathways in CATH.a cells: role of protein synthesis and protein kinases. J Neurochem,\ 998,70(4):1431-1440
59 Chong S, Shao Y, Paulus H, Benner J, Perler FB, Xu MQ. Protein splicing involving the Saccharomyces cerevisiae VMA intein. The steps in the splicing pathway, side reactions leading to protein cleavage, and establishment of an in vitro splicing system. J Biol Chem. 1996 Sep 6;271(36):22159-68.
60 Chong S, Montello GE, Zhang A, Cantor EJ, Liao W, Xu MQ, Benner J. Utilizing the C-terminal cleavage activity of a protein splicing element to purify recombinant proteins in a single chromatographic step. Nucleic Acids Res. 1998 Nov 15;26(22):5109-15..
61 Evans TC Jr, Benner J, Xu MQ. The in vitro ligation of bacterially expressed proteins using an intein from Methanobacterium thermoautotrophicum. J Biol Chem.1999 Feb 12;274(7):3923-6..
62 Southworth MW, Amaya K, Evans TC, Xu MQ, Perler FB. Purification of proteins fused to either the amino or carboxy terminus of the Mycobacterium xenopi gyrase A intein. Biotechniques. 1999 Jul;27(l):110-4, 116, 118-20..
63 Yung SL, Dela Cruz F, Hamren S, Zhu J, Tsutsumi M, Bloom JW, Caudle M,Roczniak S, Todd T, Lemoine L, MacDougall M, Shanafelt AB, Pan CQ. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J Biol Chem. 2003 Mar 21;278(12):10273-81. Epub 2003 Jan 13..
64 http://www.neb.com/nebecomm/ManualFiles/manualE6900.pdf
65 Pisegna J R, Wank S A. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci USA1999;90(13):: 6345-6349.
66 Reubi J C, Laderach U, Waser B, Gebbers J O, Robberecht P, Laissue J A.Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Research 2000; 60(11) : 3105-3112.
67 Schulz S, Rocken C, Mawrin C, Weise W, Hollt V, Schulz S. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Clin Cancer Res. 2004 Dec 15;10(24):8235-42.
68 Schmidt WE, Seebeck J, Hocker M, Schwarzhoff R, Schafer H, Fornefeld H,Morys-Wortmann C, Folsch UR, Creutzfeldt W. PACAP and VIP stimulate enzyme secretion in rat pancreatic acini via interaction with VIP/PACAP-2 receptors: additive augmentation of CCK/carbachol-induced enzyme release. Pancreas. 1993 Jul;8(4):476-87..
69 Zhao M, Sun LM, Jian RL.The role of pituitary adenylate cyclase activating polypeptide in the growth modulation of human pancreas cancinoma. Chin J Dig 2001;21:86-89.
70 Chen ZY, Chai Y F, He C, Lu C L, Wu X F. Gene Cloning and Expression of PACAP and Study of Its Biological Activity. Prog. Biochem. Biophys 2001;28:192-197.
71 Langer I, Gregoire F, Nachtergael I, De Neef P, Vertongen P, Robberecht P.Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency. Peptides 2004; 25: 275-278.
72 Igarashi H, Ito T, Pradhan TK, Mantey SA, Hou W, Coy DH, Jensen RT.Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(l) receptors. J Pharmacol Exp Ther. 2002 Nov;303(2):445-60.
73 Moro O, Wakita K, Ohnuma M, Denda S, Lerner EA, Tajima M. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist. J Biol Chem. 1999 Aug 13;274(33):23103-10.
74 Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R, Laburthe M. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem. 2000 Aug 4;275(31):24003-12.
75 O'Harte FP, Mooney MH, Flatt PR. NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes. 1999 Apr;48(4):758-65.
76 Zhang Z Z, Yang S S, Mao J F, Purification and bioactivity of recombinant human glucagons-like peptide-1, Chinese Journal of Biochemistry and Molecular Biology, 2002,18(1): 5-8
77 黄宪，王彦广，陈振初．《新编有机合成化学》．化学工业出版社，2003年，第1版，第15章，第1节，p616
78 伍越寰，李伟旭，沈晓明．《有机化学》中国科学技术大学出版社．1994年，第一版 第15章，第3节，p441
79 Coleman DT, Chen X, Sassaroli M, Bancroft C. Pituitary adenylate cyclase-activating polypeptide regulates prolactin promoter activity via a protein kinase A-mediated pathway that is independent of the transcriptional pathway employed by thyrotropin-releasing hormone. Endocrinology. 1996 Apr; 137(4): 1276-85.
80 Tohei A, Matsuzaki M, Kogo H, Antagonist of pituitary adenylate cyclase activating polypeptide suppresses prolactin secretion without changing the activity of dopamine neurons in lactating rats. Neuroendocrinology. 2001,73(1):68-74
81 Ciccarelli E, Svoboda M, De Neef P, Di Paolo E, Bollen A, Dubeaux C, Vilardaga JP, Waelbroeck M, Robberecht P. Pharmacological properties of two recombinant splice variants of the PACAP type Ⅰ receptor, transfected and stably expressed in CHO cells. Eur J Pharmacol. 1995 Feb 15;288(3):259-67.
82 Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. Eur J Pharmacol. 1996 Apr 29;302(1-3):207-14.
83 Ciccarelli E, Vilardaga JP, De Neef P, Di Paolo E, Waelbroeck M, Bollen A,Robberecht P. Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Regul Pept. 1994 Dec 15;54(2-3):397-407.
84 Svoboda M, Tastenoy M, Van Rampelbergh J, Goossens JF, De Neef P,Waelbroeck M, Robberecht P. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun.1994 Dec 30;205(3):1617-24.
85 Langlet C, Gaspard N, Nachtergael I, Robberecht P, Langer I. Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells. Peptides. 2004 Dec;25(12):2079-86.
86 Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides.1997;18(10):1555-60.
87 Gourlet P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Robberecht P. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur J Pharmacol. 1995 Dec 4;287(1):7-11.
88 Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P,Waelbroeck M. Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation. Eur J Biochem. 1999 Oct 1;265(1):449-56.
89 Gourlet P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Robberecht P. C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors.Regul Pept. 1996 Apr 23;62(2-3):125-30.
90 Jamen F, Puech R, Bockaert J, Brabet P, Bertrand G. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC. Endocrinology.2002 Apr;143(4):1253-9.
91 Yamamoto K, Hashimoto H, Tomimoto S, Shintani N, Miyazaki J, Tashiro F,Aihara H, Nammo T, Li M, Yamagata K, Miyagawa J, Matsuzawa Y, Kawabata Y,Fukuyama Y, Koga K, Mori W, Tanaka K, Matsuda T, Baba A. Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Ann N Y Acad Sci. 1998 Dec 11;865:247-52.
92 Rachdi L, Marie JC, Scharfmann R. Role for VPAC2 receptor-mediated signals in pancreas development. Diabetes. 2003 Jan;52(1):85-92.
93 Tamakawa H, Miyata A, Satoh K, Miyake Y, Matsuo H, Arimura A, Kangawa K. The augmentation of pituitary adenylate cyclase-activating polypeptide (PACAP) in streptozotocin-induced diabetic rats. Peptides. 1998;19(9): 1497-502.
94 Portela-Gomes GM, Lukinius A, Ljungberg O, Efendic S, Ahren B, Abdel-Halim SM. PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets. Regul Pept. 2003 May 15;113(1-3):31-9
95 Yamada H, Watanabe M, Yada T. Cytosolic Ca2+ responses to sub-picomolar and nanomolar PACAP in pancreatic beta-cells are mediated by VPAC2 and PAC1 receptors. Regul Pept. 2004 Dec 15;123(1-3): 147-53.
96 Jamen F, Persson K, Bertrand G, Rodriguez-Henche N, Puech R, Bockaert J, Ahren B, Brabet P. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest. 2000 May; 105(9):1307-15.
97 武振羽，张韫宏，王辉，马奉奇，环肽合成进展，化学进展，2002，14(2)：113-120
98 Chen YC, Muhlrad A, Shteyer A, Vidson M, Bab I, Chorev M. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). J Med Chem. 2002 Apr 11; 45(8): 1624-32.
99 唐艳春，田桂玲，叶蕴华，环肽合成方法的研究进展，高等学校化学学报，2000，21(7)：1056-1063
100 Tam J P, Lu YA. Synthesis of large cyclic cystine knot peptide by orthogonal coupling strategy using unprotected peptide precursor, Tetrahedron Letters, 1997,38:5599-5602.
101 Daly NL, Love S, Alewood PF, Craik DJ. Chemical synthesis and folding pathways of large cyclic polypeptides: studies of the cystine knot polypeptide kalata B1. Biochemistry. 1999 Aug 10;38(32): 10606-14..
102 Botti, P., Pallin, T. D. and Tam, J. P. Cyclic peptides: A concentration independent, thermodynamically driven approach using unprotected peptides. J. Am. Chem. Soc, 1996, 118, 10018-10024
103 Zhang, L. and Tam, J. P. Synthesis and applications of unprotected cyclic peptides as building blocks for peptide dendrimers. J. Am. Chem. Soc., 1997, 119, 2363-2370.
104 Spetzler JC, Tam JP, Self-assembly of cyclic peptides on a dendrimer: multiple cyclic antigen peptides. Pept Res. 1996 Nov-Dec;9(6):290-6.
105 Tam JP, Lu YA. A biomimetic strategy in the synthesis and fragmentation of cyclic protein. Protein Sci. 1998 Jul;7(7):1583-92
106 Yang L P, Kong X P, Yi X R. Analyzing peptides of low weights molecular with SDS-polyacrylamide gel electrophoresis, J Chinese Biotechnology. 1998;18:19-51
107 卢圣栋，《现代分子生物学实验技术》．(第二版)，中国协和医科大学出版社，第13章，p397-400
108 汪家政，范明．《蛋白技术手册》，科学出版社，第三章，“蛋白浓度测定”，p43
109 Yada T, Nakata M, Shioda S. Insulinotropin PACAP potentiates insulin action. Stimulation of glucose uptake in 3T3-LI adipocytes. Ann N Y Acad Sci. 2000;921:473-7.
2 Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept. 1992, 37(3): 287-303.
3 Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuro-endocrine and endocrine interaction. Front Neuroendocrinol.1995, 16(1): 53-88.
4 Ohkubo S, Kimura C, Ogi K, Okazaki K, Hosoya M, Onda H, Miyata A, Arimura A, Fujino M. Primary structure and characterization of the precursor to human pituitary adenylate cyclase activating polypeptide. DNA Cell Biol. 1992,11(1): 21-30.
5 Chattel N , Tonon M C , Vaudry H. Primary structure of frog pituitary adenylate cyclase activing polypeptide ( PACAP) and effects of ovine PACAP on frog pituitary.Endocrinology. 1991, 129 (6): 3367-3371
6 Shioda S, Shuto Y, Somogyvari-Vigh A, Legradi G, Onda H, Coy D H, Nakajo S and Arimura A. Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain. Neurosci Res. 1997, 28(4):345-354
7 Wei Y, Mojsov S. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J Neuroendocrinol.1996,8(11): 811-817
8 Qiao L P, Li X L. Resent development of research on pituitary adenylate cyclase activating polypeptide and its receptors. J Modern Clinical Medical Bioengineering.2003, 9(1):61-63
9 David Vaudry, Bruno J. Gonzalez, Magali Basille, Laurent Yon, Alain Fournier and Hubert Vaudry. Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors:From Structure to Function. Pharmacological Reviews, 2000, 52(2): 269-324
10 Harmar A J, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna J R.Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). Pharmacol Rev, 1998, 50(2): 265-270.
11 Kamaishi H, Endoh T, Suzuki TMultiple signal pathways coupling VIP and PACAP receptors to calcium channels in hamster submandibular ganglion neurons. Auton Neurosci. 2004 Mar 31;111(1):15-26.
12 See V, Koch B, Loeffier JP. C2-ceramide and reactive oxygen species inhibit pituitary adenylate cyclase activating polypeptide (PACAP) - induced cyclic -AMP- dependent signalling pathway. J Neurochem, 2001,76(3) :778-788
13 Van Rampelbergh J, Poloczek P, Francoys I, Delporte C, Winand J, Robberecht P, Waelbroeck MThe pituitary adenylate cyclase activating polypeptide (PACAP Ⅰ) and VIP (PACAP Ⅱ VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochim Biophys Acta. 1997 Jun 27;1357(2):249-255.
14 Mazzocchi G, Malendowicz LK, Neri G, Andreis PG, Ziolkowska A, Gottardo L, Nowak KW, Nussdorfer GG. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland, Int J Mol Med. 2002 Mar;9(3):233-43.
15 Sacchetti B, Lorenzini CA, Baldi E, Bucherelli C, Roberto M, Tassoni G, Brunelli M Pituitary adenylate cyclase-activating polypeptide hormone (PACAP) at very low dosages improves memory in the rat. Neurobiol Learn Mere. 2001 Jul;76(1):1-6.
16 Hashimoto H, Shintani N, Tanaka K, Mori W, Hirose M, Matsuda T, Sakaue M, Miyazaki J, Niwa H, Tashiro F, Yamamoto K, Koga K, Tomimoto S, Kunugi A, Suetake S, Baba A Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP) Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13355-60. Epub 2001 Oct 30.
17 Yuhara A, Nishio C, Abiru Y, Hatanaka H, Takei N. PACAP has a neurotrophic effect on cultured basal forebrain cholinergic neurons from adult rats. Brain Res Dev Brain Res. 2001 Nov 26;131(1-2):41-5.
18 Somogyvari-Vigh A, Pan W, Reglodi D, Kastin AJ, Arimura A. Effect of middle cerebral artery occlusion on the passage of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier in the rat. Regul Pept. 2000 Jul 28;91(1-3):89-95.
19 董艳，何成，韩唏，垂体腺苷酸环化酶激活肽减轻大鼠缺血性 脑水肿作用的实验研究，中国应用生理学杂志，2002，18(2)：121-31
20 Zhou CJ, Shioda S, Yada T, Inagaki N, Pleasure SJ, Kikuyama S. PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr Protein Pept Sci. 2002 Aug;3(4):423-39.
21 Journot L, Spengler D, Pantaloni C, Dumuis A, Sebben M and Bockaert J. The PACAP receptor: Generation by alternative splicing of functional diversity among G protein-coupled receptors in nerve cells. Semin Cell Biol,l994, 5(4): 263-272
22 Cazillis M, Gonzalez BJ, Billardon C, Lombet A, Fraichard A, Samarut J, Gressens P, Vaudry H, Rostene W. VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells. Eur J Neurosci. 2004 Feb;19(4):798-808.
23 Chang Q, Deng Y P, Liu S H, Morphologic study on PACAP protecting vascular smooth muscle cell from damage by LDL. Progress of Anatomical Sciences 1999; 5:347-349.
24 Linden A, Hansson, L Andersson A, Palmqvist M, Arvidsson P, Lofdahl C-G, Larsson P, Lotvall J. Bronchodilation by an inhaled VPAC2 receptor agonist in patients with stable asthma. Thorax 2003;58:217-221 (http://thorax.bmjjournals.com/cgi/content/full/58/3/217)
25 Akesson L, Ahren B, Manganiello VC, Hoist LS, Edgren G, Degerman E. Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes. Endocrinology. 2003 Dec;144(12):5293-9. Epub 2003 Aug 28.
26 West AP, McKinnell C, Sharpe RM, Saunders PT. Pituitary adenylate cyclase activating polypeptide can regulate testicular germ cell protein synthesis in vitro. J Endocrinol. 1995 Feb;144(2):215-23.
27 Guidone G, Muller D, Vogt K, Mukhopadhyay AK. Characterization of VIP and PACAP receptors in cultured rat penis corpus cavernosum smooth muscle cells and their interaction with guanylate cyclase-B receptors. Regul Pept. 2002 Oct 15;108(2-3):63-72..
28 Ko C, In Y H, Park-Sarge O K. Role of progesterone receptor activation in pituitary adenylate cyclase activating polypeptide gene expression in rato vary.Endocrinology, 1999, 140 (11):5185—5194
29 Delgado M, Abad C, Martinez C, Juarranz MG, Leceta J, Ganea D, Gomariz RP.PACAP in immunity and inflammation. Ann N Y Acad Sci. 2003 May;992:141-57.
30 Abad C, Martinez C, Leceta J, Gomariz RP, Delgado M. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol. 2001 Sep 15;167(6):3182-9.
31 Martinez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodriguez-Henche N, Brabet P, Leceta J, Gomariz RP. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci USA. 2002 Jan 22;99(2): 1053-8. Epub 2002 Jan 15.
32 Pozo D. VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Meal 2003 May;9(5):211-7.
33 Hannibal J, Hindersson P, Knudsen SM, Georg B, Fahrenkrug J. The photopigment melanopsin is exclusively present in pituitary adenylate cyclase-activating polypeptide-containing retinal ganglion cells of the retinohypothalamic tract. J Neurosci. 2002 Jan 1;22(1):RC191.
34 杜鹃，王刚，孔德虎，垂体腺苷酸环化酶激活肽与2型糖尿病，国外医学内分泌学分册，2003，23：7-9
35 Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands. Mol Pharmacol. 1999 Dec;56(6): 1280-7.
36. Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor. Peptides. 2000 Oct;21(10): 1543-9.
37 Igarashi H, Ito T, Pradhan Y K, Mantey S A, Hou W, Coy D H, Jensen R T. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC2 receptors in human and rat and comparison to the pharmacophore for VPAC1 receptors, JPET, 2002 303(2):445-460
38 Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J, Dela Cruz F, Peng X, Chen H, Yung SL, Hamren S, Livingston JN, Pan CQ. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes. 2002 May;51(5):1453-60.
39 Umemoto N, Ohya Y, Anraku Y. VMA11, a novel gene that encodes a putative proteolipid, is indispensable for expression of yeast vacuolar membrane H(+)-ATPase activity. J Biol Chem. 1991 Dec 25;266(36):24526-32..
40 Paulus H. Protein splicing: A novel form of gene expression and paradigm for self2catalyzed protein rearrangements. Pure and Aplied Chemistry, 1998,70(1): 1-8.
41 Lambowitz AM, Belfort M. Introns as mobile genetic elements. Annu Rev Biochem. 1993;62:587-622.
42 Xu M Q, Evans T C Jr. Intein-mediated ligation and cyclization of expressed proteins. Methods, 2001, 24(3): 257-27
43 Xu M Q, Paulus H, Chong S. Fusions to self-splicing inteins for protein purification. Methods Enzymol, 2000,326: 376-41
44 Evans T CJr, Benner J, Xu MQ. The cyclization and polymerization of bacterially expressed proteins using modified self2splicing inteins. JBiol Chem, 1999, 274(26): 18359-18363
45 Scott C P, Abel2Santos E, Wall M, Wahnon D C, Benkovic S J Production of cyclic peptides and proteins in vivo. Proc Natl Acad Sci USA,1999,96 (24): 13638-1364
46 Otomo T, Teruya K, Uegaki K, Yamazaki T, Kyogoku Y. Improved segmental isotope labeling of proteins and application to a larger pro2 tein. J Biomol NMR, 1999, 14(2): 105-114
47 许乃武，基因工程原理，第二册，第三章，第8节．
48 Wei Y, Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiologica Scandinavica, 1996, 157(3): 355-362
49 Schafer H, Lettau P, Trauzold A, Banasch M, Schmidt WE. Human PACAP response gene 1 (p22/PRG1): proliferation associated expression in pancreatic carcinoma cells. Pancreas, 1999, 8(4):378-84
50 Elli nger S, Mach M, Korn K, Jahn G. Cleavage and purification of prokaryotically expressed HIV gag and env fusion proteins for detection of HIV antibodies in the ELISA. Virology,1991,180(2): 811-813.
51 Guan K L, Dixon J E, Eukaryotic proteins expressed in E. coli an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-trans-ferase. Anal Biochem, 1991,192(2) :262-268
52 Zheng Rong, Hu Yi, Zhu Chunbao, et al. Cloning of IL-2 gene in plasmid pMAL-cR1 and expression and purification of IL-2 protein, Chinese Journal of Parmaceuticals, 1994,25(6):243-246
53 Feng Dan, Yuan Yong, Zhang Yingmei, et al. Citraconic anhydride modification on the recombinant protein expressed in E. coli. Prog Biochem Biophys, 1996,23(6):541-544
54 Newton D L, Xue Y, Olson K A, et al. Angiogenin single-chain immunofusions:influence of peptide linkers and spacers between fusion proteins domains.Biochemistry, 1996,35(2):545-553
55 Liu X B, Li S H, Liang X B, Kong X Y. A system of efficient expression and rapid purification of recombinant polypeptides. Bull Acad Mi Med Sci, 1996,120(1):62-65
56 He M, Jin L, Austen B. Specificity of factor Xa in the cleavage of fusion proteins.J Protein Chem, 1993 ,12(1):1-5
57 Zhao M, Wang G, Du B, Nie S X, Jiang R L. Stimulation effect of PACAP on the growth of cell line JF3O5 of human pancreas carcinoma. J Chin Med Univ,2001,30(3):204-208
58 Muller A, Lutz-Bucher B, Kienlen-Campard P, Koch B, Loeffler J P. Continuous activation of pituitary adenylate cyclase-activating polypeptide receptors elicits antipodal effects on cyclic AMP and inositol phospholipid signaling pathways in CATH.a cells: role of protein synthesis and protein kinases. J Neurochem,\ 998,70(4):1431-1440
59 Chong S, Shao Y, Paulus H, Benner J, Perler FB, Xu MQ. Protein splicing involving the Saccharomyces cerevisiae VMA intein. The steps in the splicing pathway, side reactions leading to protein cleavage, and establishment of an in vitro splicing system. J Biol Chem. 1996 Sep 6;271(36):22159-68.
60 Chong S, Montello GE, Zhang A, Cantor EJ, Liao W, Xu MQ, Benner J. Utilizing the C-terminal cleavage activity of a protein splicing element to purify recombinant proteins in a single chromatographic step. Nucleic Acids Res. 1998 Nov 15;26(22):5109-15..
61 Evans TC Jr, Benner J, Xu MQ. The in vitro ligation of bacterially expressed proteins using an intein from Methanobacterium thermoautotrophicum. J Biol Chem.1999 Feb 12;274(7):3923-6..
62 Southworth MW, Amaya K, Evans TC, Xu MQ, Perler FB. Purification of proteins fused to either the amino or carboxy terminus of the Mycobacterium xenopi gyrase A intein. Biotechniques. 1999 Jul;27(l):110-4, 116, 118-20..
63 Yung SL, Dela Cruz F, Hamren S, Zhu J, Tsutsumi M, Bloom JW, Caudle M,Roczniak S, Todd T, Lemoine L, MacDougall M, Shanafelt AB, Pan CQ. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J Biol Chem. 2003 Mar 21;278(12):10273-81. Epub 2003 Jan 13..
64 http://www.neb.com/nebecomm/ManualFiles/manualE6900.pdf
65 Pisegna J R, Wank S A. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci USA1999;90(13):: 6345-6349.
66 Reubi J C, Laderach U, Waser B, Gebbers J O, Robberecht P, Laissue J A.Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Research 2000; 60(11) : 3105-3112.
67 Schulz S, Rocken C, Mawrin C, Weise W, Hollt V, Schulz S. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Clin Cancer Res. 2004 Dec 15;10(24):8235-42.
68 Schmidt WE, Seebeck J, Hocker M, Schwarzhoff R, Schafer H, Fornefeld H,Morys-Wortmann C, Folsch UR, Creutzfeldt W. PACAP and VIP stimulate enzyme secretion in rat pancreatic acini via interaction with VIP/PACAP-2 receptors: additive augmentation of CCK/carbachol-induced enzyme release. Pancreas. 1993 Jul;8(4):476-87..
69 Zhao M, Sun LM, Jian RL.The role of pituitary adenylate cyclase activating polypeptide in the growth modulation of human pancreas cancinoma. Chin J Dig 2001;21:86-89.
70 Chen ZY, Chai Y F, He C, Lu C L, Wu X F. Gene Cloning and Expression of PACAP and Study of Its Biological Activity. Prog. Biochem. Biophys 2001;28:192-197.
71 Langer I, Gregoire F, Nachtergael I, De Neef P, Vertongen P, Robberecht P.Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency. Peptides 2004; 25: 275-278.
72 Igarashi H, Ito T, Pradhan TK, Mantey SA, Hou W, Coy DH, Jensen RT.Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(l) receptors. J Pharmacol Exp Ther. 2002 Nov;303(2):445-60.
73 Moro O, Wakita K, Ohnuma M, Denda S, Lerner EA, Tajima M. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist. J Biol Chem. 1999 Aug 13;274(33):23103-10.
74 Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R, Laburthe M. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem. 2000 Aug 4;275(31):24003-12.
75 O'Harte FP, Mooney MH, Flatt PR. NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes. 1999 Apr;48(4):758-65.
76 Zhang Z Z, Yang S S, Mao J F, Purification and bioactivity of recombinant human glucagons-like peptide-1, Chinese Journal of Biochemistry and Molecular Biology, 2002,18(1): 5-8
77 黄宪，王彦广，陈振初．《新编有机合成化学》．化学工业出版社，2003年，第1版，第15章，第1节，p616
78 伍越寰，李伟旭，沈晓明．《有机化学》中国科学技术大学出版社．1994年，第一版 第15章，第3节，p441
79 Coleman DT, Chen X, Sassaroli M, Bancroft C. Pituitary adenylate cyclase-activating polypeptide regulates prolactin promoter activity via a protein kinase A-mediated pathway that is independent of the transcriptional pathway employed by thyrotropin-releasing hormone. Endocrinology. 1996 Apr; 137(4): 1276-85.
80 Tohei A, Matsuzaki M, Kogo H, Antagonist of pituitary adenylate cyclase activating polypeptide suppresses prolactin secretion without changing the activity of dopamine neurons in lactating rats. Neuroendocrinology. 2001,73(1):68-74
81 Ciccarelli E, Svoboda M, De Neef P, Di Paolo E, Bollen A, Dubeaux C, Vilardaga JP, Waelbroeck M, Robberecht P. Pharmacological properties of two recombinant splice variants of the PACAP type Ⅰ receptor, transfected and stably expressed in CHO cells. Eur J Pharmacol. 1995 Feb 15;288(3):259-67.
82 Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. Eur J Pharmacol. 1996 Apr 29;302(1-3):207-14.
83 Ciccarelli E, Vilardaga JP, De Neef P, Di Paolo E, Waelbroeck M, Bollen A,Robberecht P. Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Regul Pept. 1994 Dec 15;54(2-3):397-407.
84 Svoboda M, Tastenoy M, Van Rampelbergh J, Goossens JF, De Neef P,Waelbroeck M, Robberecht P. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun.1994 Dec 30;205(3):1617-24.
85 Langlet C, Gaspard N, Nachtergael I, Robberecht P, Langer I. Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells. Peptides. 2004 Dec;25(12):2079-86.
86 Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides.1997;18(10):1555-60.
87 Gourlet P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Robberecht P. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur J Pharmacol. 1995 Dec 4;287(1):7-11.
88 Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P,Waelbroeck M. Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation. Eur J Biochem. 1999 Oct 1;265(1):449-56.
89 Gourlet P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Robberecht P. C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors.Regul Pept. 1996 Apr 23;62(2-3):125-30.
90 Jamen F, Puech R, Bockaert J, Brabet P, Bertrand G. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC. Endocrinology.2002 Apr;143(4):1253-9.
91 Yamamoto K, Hashimoto H, Tomimoto S, Shintani N, Miyazaki J, Tashiro F,Aihara H, Nammo T, Li M, Yamagata K, Miyagawa J, Matsuzawa Y, Kawabata Y,Fukuyama Y, Koga K, Mori W, Tanaka K, Matsuda T, Baba A. Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Ann N Y Acad Sci. 1998 Dec 11;865:247-52.
92 Rachdi L, Marie JC, Scharfmann R. Role for VPAC2 receptor-mediated signals in pancreas development. Diabetes. 2003 Jan;52(1):85-92.
93 Tamakawa H, Miyata A, Satoh K, Miyake Y, Matsuo H, Arimura A, Kangawa K. The augmentation of pituitary adenylate cyclase-activating polypeptide (PACAP) in streptozotocin-induced diabetic rats. Peptides. 1998;19(9): 1497-502.
94 Portela-Gomes GM, Lukinius A, Ljungberg O, Efendic S, Ahren B, Abdel-Halim SM. PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets. Regul Pept. 2003 May 15;113(1-3):31-9
95 Yamada H, Watanabe M, Yada T. Cytosolic Ca2+ responses to sub-picomolar and nanomolar PACAP in pancreatic beta-cells are mediated by VPAC2 and PAC1 receptors. Regul Pept. 2004 Dec 15;123(1-3): 147-53.
96 Jamen F, Persson K, Bertrand G, Rodriguez-Henche N, Puech R, Bockaert J, Ahren B, Brabet P. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest. 2000 May; 105(9):1307-15.
97 武振羽，张韫宏，王辉，马奉奇，环肽合成进展，化学进展，2002，14(2)：113-120
98 Chen YC, Muhlrad A, Shteyer A, Vidson M, Bab I, Chorev M. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). J Med Chem. 2002 Apr 11; 45(8): 1624-32.
99 唐艳春，田桂玲，叶蕴华，环肽合成方法的研究进展，高等学校化学学报，2000，21(7)：1056-1063
100 Tam J P, Lu YA. Synthesis of large cyclic cystine knot peptide by orthogonal coupling strategy using unprotected peptide precursor, Tetrahedron Letters, 1997,38:5599-5602.
101 Daly NL, Love S, Alewood PF, Craik DJ. Chemical synthesis and folding pathways of large cyclic polypeptides: studies of the cystine knot polypeptide kalata B1. Biochemistry. 1999 Aug 10;38(32): 10606-14..
102 Botti, P., Pallin, T. D. and Tam, J. P. Cyclic peptides: A concentration independent, thermodynamically driven approach using unprotected peptides. J. Am. Chem. Soc, 1996, 118, 10018-10024
103 Zhang, L. and Tam, J. P. Synthesis and applications of unprotected cyclic peptides as building blocks for peptide dendrimers. J. Am. Chem. Soc., 1997, 119, 2363-2370.
104 Spetzler JC, Tam JP, Self-assembly of cyclic peptides on a dendrimer: multiple cyclic antigen peptides. Pept Res. 1996 Nov-Dec;9(6):290-6.
105 Tam JP, Lu YA. A biomimetic strategy in the synthesis and fragmentation of cyclic protein. Protein Sci. 1998 Jul;7(7):1583-92
106 Yang L P, Kong X P, Yi X R. Analyzing peptides of low weights molecular with SDS-polyacrylamide gel electrophoresis, J Chinese Biotechnology. 1998;18:19-51
107 卢圣栋，《现代分子生物学实验技术》．(第二版)，中国协和医科大学出版社，第13章，p397-400
108 汪家政，范明．《蛋白技术手册》，科学出版社，第三章，“蛋白浓度测定”，p43
109 Yada T, Nakata M, Shioda S. Insulinotropin PACAP potentiates insulin action. Stimulation of glucose uptake in 3T3-LI adipocytes. Ann N Y Acad Sci. 2000;921:473-7.